Read the REPORT.
The iPrEx study considered whether taking the drug Truvada on a daily basis, in combination with safe sex counseling, could prevent gay and bisexual men from becoming infected with HIV. In November, the study reported that Pre-Exposure Prophylaxis, or PrEP, could be as much as 73 percent effective in preventing infection if the drug Truvada was taken at least 90 percent of the time.
Despite positive results, PrEP is not likely to be widely implemented until planned demonstration projects are completed that assess how effective it can be outside of a rigorously controlled clinical study. These projects, which will be conducted in San Francisco and Boston, also seek to identify the most effective setting for PrEP delivery, methods for supporting adherence to the PrEP regimen, and targeting and recruitment strategies for assuring PrEP use among those at highest risk for infection, among other questions. Project Inform advocated for these two demonstration projects and is advocating for projects in additional US cities.
A key issue regarding PrEP delivery involves how it will be paid for and for whom. Project Inform is releasing a report that discusses questions regarding PrEP financing and makes key recommendations about moving forward to assure that this promising prevention strategy is accessible to gay and bisexual men at highest risk for HIV infection.